Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gossamer Bio, Inc. - Common Stock (NQ:GOSS)

2.220 -0.090 (-3.90%)
Streaming Delayed Price Updated: 11:30 AM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gossamer Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Recap: Gossamer Bio Q3 Earnings
 
Via Benzinga
Analyst Expectations for Gossamer Bio's Future
 
Via Benzinga
Analyst Ratings for Gossamer Bio
 
Via Benzinga
Gossamer Bio And 2 Other Stocks Under $1 Insiders Are Buying
The Dow Jones closed higher by around 490 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs
From Gossamer Bio, Inc.
Via Business Wire
After Pausing Recruitment, Gossamer Bio Terminates All Studies With CNS Lymphoma Candidate
 
Via Benzinga
Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Gossamer Bio Announces $212 Million Private Placement Financing
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces TORREY Data to be Featured at American Thoracic Society 2023 International Conference
From Gossamer Bio, Inc.
Via Business Wire
Why MIND Technology Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers WeTrade Group, Inc. (NASDAQ: WETG) shares climbed 140.3% to $20.28. WeTrade launched large-scale language processing models to increase product applications in the field of artificial... 
Via Benzinga
Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Skillz And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones closed higher by around 80 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Why Bed Bath & Beyond Shares Are Trading Lower By Around 24%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the trading week with a breakdown of the biggest pre-market stock movers for Monday and what's behind that movement! 
Via InvestorPlace
Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
Why Titan Machinery Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) shares jumped 40.2% to $2.5109 after the company announced the successful completion of a Phase 2A clinical trial evaluating the safety and efficacy... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Analyst Downgrades Gossamer Bio As Merck's Sotatercept Might Overshadow Seralutinib's Success
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.